油酰羟乙磺酸钠 | 142-15-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 油酰羟乙磺酸钠
• 中文别名: (Z)-9-十八烯酸-2-磺乙基酯钠盐
• CAS: 142-15-4
• 化学式: C20H38NaO5S
• 分子量: 413.6
• InChiKey: HEFGVOBFSXKIKL-KVVVOXFISA-N

物化性质

• LogP：
  6.361 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  5.07
• 重原子数：
  27
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  89
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2909199090

文献信息

• [EN] CBD PRODRUGS, COMPOSITIONS, AND METHODS OF ADMINISTERING CBD AND CBD PRODRUGS<br/>[FR] PROMÉDICAMENTS CBD, COMPOSITIONS ET PROCÉDÉS D'ADMINISTRATION DE CBD ET DE PROMÉDICAMENTS CBD
  申请人：KALYTERA THERAPEUTICS INC

  公开号：WO2018096504A1

  公开（公告）日：2018-05-31

  Compounds of Formula (I), including stereoisomers and salts thereof, and compositions, methods of treatment and prevention, and methods of preparing, the same: Formula (I) wherein X is O or a direct bond; wherein when X is O, R1 and R2 are each independently selected from -H, -SO3Na, -PO(ONa)2, -PO(OCH2CH3), -CH2PO(ONa)2, -NO2, -(L)-valine ester, -(L)-N-methyl arginine ester, -α-guanidinoglutaric acid ester, -2-iminobiotin ester, -3- hydroxy anthranilic acid ester, -(L)-nitroarginine ester, -(L)- N5-(1-iminoethyl)-(L)- ornithine (NIO) ester, -(L)-N,N dimethylarginine ester, -(L)- N6-(1-iminoethyl)-(L)-lysine (NIL) ester, -(L)- N-monomethyl-(L)-arginine (NMMA) ester, -N-amino-(L)-arginine ester, -N-propyl-(L)-arginine ester, -S-methyl-(L)-thiocitrulline ester, -methyl-(L)-NIO ester, - vinyl -(L)-NIO ester, and -propenyl-(L)-NK) ester; and wherein when X is a direct bond, R1 and R2 are Formula (II).

  化合物的化学式（I），包括其立体异构体和盐，以及其组合物、治疗和预防方法，以及其制备方法：化学式（I）其中X为O或直接键；其中当X为O时，R1和R2分别独立选择自-H、-SO3Na、-PO(ONa)2、-PO(OCH2CH3)、-CH2PO(ONa)2、-NO2、-(L)-缬氨酸酯、-(L)-N-甲基精氨酸酯、-α-瓜氨酸戊二酸酯、-2-亚基生物素酯、-3-羟基蒽醌酸酯、-(L)-硝基精氨酸酯、-(L)-N5-(1-亚基乙基)-(L)-鸟氨酸（NIO）酯、-(L)-N,N-二甲基精氨酸酯、-(L)-N6-(1-亚基乙基)-(L)-赖氨酸（NIL）酯、-(L)-N-单甲基-(L)-精氨酸（NMMA）酯、-N-氨基-(L)-精氨酸酯、-N-丙基-(L)-精氨酸酯、-S-甲基-(L)-硫基瓜氨酸酯、-甲基-(L)-NIO酯、-乙烯基-(L)-NIO酯和-丙烯基-(L)-NK）酯；当X为直接键时，R1和R2为化学式（II）。
• [EN] METHODS AND COMPOSITIONS FOR TREATMENT OF PRADER-WILLI SYNDROME<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DU SYNDROME DE PRADER-WILLI
  申请人：YISSUM RES DEV CO

  公开号：WO2017179058A1

  公开（公告）日：2017-10-19

  The present invention provides pharmaceutical compositions comprising a fatty acid amide of an amino acid as defined herein, such as oleoyl-α-methyl-serine, or a stereoisomer or salt thereof, for improving, i.e., increasing or preventing loss of, bone mineral density and/or treating osteoporosis in patients suffering from Prader-Willi syndrome; and methods of use.

  本发明提供了一种药物组合物，其中包括本文所定义的一种氨基酸脂肪酰胺，例如油酰-α-甲基-丝氨酸或其立体异构体或盐，用于改善，即增加或预防骨密度的流失，和/或治疗患有普拉德-威利综合症的患者的骨质疏松症；以及使用方法。
• Method of reducing undesirable activities of biological and pharmaceutical products
  申请人：New York Blood Center, Inc.

  公开号：EP0050061A2

  公开（公告）日：1982-04-21

  A method of reducing or suppressing undesirable activities like pyrogenicity, hepatitis infectivity and clotting activation of biological or pharmaceutical products, including plasma protein products, or of products for treating them like sterile filters or chromatographic materials. The products are treated by prolonged contact with a solution or suspension of from about 0,25% to about 10% by weight of a non-denaturating amphiphile.

  一种降低或抑制生物或药物产品（包括血浆蛋白产品）或用于处理这些产品（如无菌过滤器或色谱材料）的热原性、肝炎感染性和凝血活化等不良活性的方法。 处理这些产品的方法是将其与一种非变性亲和剂溶液或悬浮液（按重量计约为 0.25%至约 10%）长时间接触。
• An ultrapurification process for factor VIII:C
  申请人：BAXTER INTERNATIONAL INC. (a Delaware corporation)

  公开号：EP0286323A2

  公开（公告）日：1988-10-12

  A process for purifying polypeptides comprising contacting an immobilized antibody specifically binding a polypeptide with that polypeptide, desorbing the polypeptide from the antibody which had adsorbed it, eluting the polypeptide from the presence of the antibody, passing the eluted polypeptide through an affinity region capable of binding the polypeptide, binding the polypeptide in the affinity region and passing contaminants through said region, and eluting the purified polypeptide.

  一种纯化多肽的工艺，包括将特异性结合多肽的固定化抗体与多肽接触，从吸附了多肽的抗体中解吸多肽，将多肽从抗体中洗脱出来，将洗脱出来的多肽通过能够结合多肽的亲和区，在亲和区中结合多肽并将杂质通过所述区域，然后洗脱纯化的多肽。
• Lubricants and fluids containing thiocarbamates and phosphonates
  申请人：The Lubrizol Corporation

  公开号：EP0712924A1

  公开（公告）日：1996-05-22

  Oil based compositions including a compound of the structure R₁R₂N - C(X)S - (CR₃R₄)aY, where R₁, R₂, R₃, and R₄ are hydrogen or hydrocarbyl groups, X is oxygen or sulfur, Y is an activating group such as an ester, and a is 1 or 2; a sulfur-containing phosphonic acid or a salt thereof, and optionally a surfactant, exhibit good anti-wear performance.

  包括结构为 R₁R₂N - C(X)S - (CR₃R₄)aY 的化合物的油基组合物，其中 R₁、R₂、R₃ 和 R₄ 是氢或烃基，X 是氧或硫，Y 是活化基团如酯，a 是 1 或 2；含硫膦酸或其盐以及表面活性剂具有良好的抗磨损性能。